Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
CRO Sygnature Discovery plans to send 60 UK staffers packing
(2d)
Corcept submitted lead asset for approval despite FDA flagging risk of ‘significant review issues’
(2d)
Moderna's latest CMO steps down after barely a year
(2d)
Chugai drops only AI-assisted antibody from pipeline but still holds high hopes for tech
(2d)
Amgen jilts Kyowa, exiting $400M autoimmune pact after running vast pivotal program
(2d)
AstraZeneca returns to China’s CSPC for $4.7B obesity deal
(2d)
Moderna offloads late-stage rare disease drug to Recordati for $50M upfront
(2d)
Chutes & Ladders—Cardiff churns C-suite to advance cancer candidate
(3d)
Inside Henlius’ global growth strategy
(3d)
Formation Bio’s China shopping spree continues with $500M biobucks autoimmune pact
(3d)
BioPharma Dive
Amgen gives up on its once-prized eczema drug
(2d)
AstraZeneca leans into obesity, striking wide-ranging alliance with China’s CSPC
(2d)
Politicization runs deeper than ever at FDA, risking long-term impacts
(2d)
The biopharma industry outlook on 2026: Optimism and tension
(3d)
Sanofi expects vaccine sales growth to dip amid ‘challenging environment’
(3d)
AstraZeneca strengthens China ties with planned $15B investment
(3d)
Moderna holds a ‘garage sale’; Roche defends obesity drug data
(3d)
Tenpoint wins FDA nod for combination presbyopia eye drop
(3d)
Lilly bets on Seamless, delving further into genetic medicine for hearing loss
(4d)
Drugs for cancer, arthritis and HIV on Medicare’s list for 2028 price cuts
(4d)
Endpoints News
Big Pharma earnings kick off; Third-round IRA drugs selected; Hengrui’s trailblazing moment; and more
(1d)
FDA says it explained issues early on for Corcept's rejected Cushing's syndrome drug
(2d)
Bitterroot reverts to preclinical biotech in CD47 as CEO leaves
(2d)
CHMP opposes Lilly’s Mounjaro in heart failure, backs Novo’s Kayshild
(2d)
Ultragenyx resubmits gene therapy for rare neuro disease to FDA
(2d)
Quince's steroid therapy for rare disease fails, shares tank
(2d)
Moderna licenses Phase 3 asset to Recordati; ProMIS' private placement
(2d)
Amgen ends partnership with Kyowa Kirin on immunology drug, despite Phase 3 wins
(2d)
Lilly unveils $3.5B factory that will make retatrutide and other obesity drugs
(2d)
Janux hires CMO after T cell engager deal with Bristol Myers; A batch of appointments at Lexeo
(2d)
BioSpace
Despite Wide Support for Rare Disease, Voucher Program Caught Up in Senate's ICE Fight
(2d)
FDA’s Multiple Myeloma Guidance Highlights Decade of Success
(2d)
TrumpRx Delayed Amid Potential Anti-Kickback Concerns
(2d)
Moderna Teams With Recordati on Rare Disease mRNA Therapy for up to $160M
(2d)
AstraZeneca’s China Trip Yields CSPC Obesity Deal Worth $1.2B Upfront
(2d)
Sanofi Moves Away From mRNA Flu Vaccine as CEO Projects Confidence
(2d)
Summit’s Potential Keytruda Rival Gets November FDA Decision Date
(2d)
Biotech’s Next Chapter: Asset-Centric Deals and Shifting Alpha at JPM 2026
(3d)
AstraZeneca Pledges $15B More in Chinese Investments for Cell Therapies, Radiopharma
(3d)
Sanofi Suffers Another Sales Dip For 'Gift to Public Health' Vaccines
(3d)
STAT News
STAT readers on shared decision-making, prostate cancer screening, and more
(1d)
Up and down the ladder: The latest comings and goings
(2d)
New rule would force PBMs to disclose drug rebates and other fees
(2d)
Newsom files a civil rights complaint against CMS’ Oz in latest feud with the Trump administration
(2d)
AstraZeneca looks to China for obesity drug candidates
(2d)
We’re reading about TrumpRx questions, drugmakers lowering some prices, and more
(2d)
NIH announces first strategic plan for disability health research
(2d)
7 pediatric bioethicists: Proposed ban on Medicaid funding for hospitals providing gender-affirming care for minors is deeply unethical
(2d)
The food nationalism of the new dietary guidelines
(2d)
Tenuous biomedical funding has put first-year Ph.D. students in a bind
(2d)
BioPharma Trend
How Digital Health Technologies are Reshaping Clinical Development
(7h)
This AI Ready Single Molecule Proteomics $1.6M Grant Targets Parkinson’s Alpha Synuclein
(3d)
Eli Lilly Strikes Up to $1.1B Gene Editing Deal with German Startup
(4d)
FDA Greenlights First Human Trial of Epigenetic ‘Rejuvenation’ Therapy for Vision Loss
(4d)
This Company Claims World-First AI Models For Programmable Gene Insertion
(4d)
Antheia Adds $24M in Series C Extension to Expand U.S. Biosynthetic Drug Manufacturing
(5d)
In Another Major R&D Deal, Insilico Taps Chinese Pharma for AI-Designed Cardiometabolic Drugs
(5d)
Insilico Medicine Launches AI Gym for LLMs and Secures FDA Clearance for AI-Designed NLRP3 Inhibitor
(6d)
Neurotech Trends in 2025: When Use Cases Started Driving Design
(1w)
“ChatGPT for Doctors” Raises $250M Series D at $12B Valuation
(1w)
Drug Channels
From Cost Center to Insights Center: How Patient Support Will Go Beyond the Call in 2026
(2d)
Drug Channels News Roundup, January 2026: Cuban vs. Optum, McKesson’s Biosimilar Play, States vs. Accumulators, 340B Windfalls, and Ozempic Ads
(5d)
New Drug Launches in a Self-Pay World: Why Access Strategy Matters as Much as Innovation
(1w)
The Big Three PBMs’ 2026 Formulary Exclusions: MFP, Private Label Biosimilars, and Direct-to-Patient Threats for PBMs
(1w)
The Net Pricing Revolution in the Drug Channel: What’s Deflating the Gross-to-Net Bubble
(3w)
NEW: The Drug Channels 2026 Video Webinar Series
(3w)
Targeted Reach, Tighter Relationships: Why Rare Disease Launches Are Different
(3w)
U.S. Brand-Name Drug Prices Fell in 2025 as the Net Pricing Drug Channel Emerges
(4w)
Drug Channels Leadership Forum 2026: Request an Invitation Before It’s Too Late!
(4w)
Drug Channels News Roundup, December 2025: The Net Pricing Drug Channel (#NPDC) Era, LillyDirect, My $0.02 on New MFPs, PBMs in Medicaid—and DCLF 2026
(1mo)
European Biotechnology Magazine
Sanofi ends 2025 on a high, but trims R&D priorities
(2d)
CDMOs dominate the headlines – and Lonza delivers a clear message of strength
(2d)
Vetter: a multi-million-euro investment for new CDMO facility boost for Saarland/Germany
(2d)
After a turbulent phase: a new milestone from Takeda for Heidelberg Pharma
(3d)
Tenpoint wins FDA approval for presbyopia eye drop and raises $235 million
(3d)
Roche: strong growth in all world regions and a full pipeline in late stage
(3d)
Sensorion raised €60M backed by €20M from Sanofi to advance gene therapies for hearing loss
(4d)
China again: Boehringer turns to Shanghai for IBD bispecific
(4d)
Dresden biotech Seamless lands up to $1.1B Eli Lilly deal for gene therapy hearing loss
(4d)
From cell therapy to combat rifles: Genenta bets its future on becoming Italy’s national-security dealmaker
(5d)
Drug Hunter
lanifibranor (IVA-337)
(2d)
2025 Novel Large Molecule FDA Drug Approvals
(3d)
ADCs With Topoisomerase I Inhibitor Payloads Are Challenging Standards of Care in Oncology
(4d)
December 2025 Patent Highlights
(5d)
Hepatotoxicity Headaches: One of the Hardest Risks to De-Risk
(6d)
Section 3: Ligand Binding Basics
(6d)
2025 Molecules of the Year: Nominate!
(1w)
December 2025
(1w)
2025 Novel Small Molecule FDA Drug Approvals
(1w)
ziftomenib
(2w)
Labiotech.EU
Johnson & Johnson’s pipeline strategy: What does 2026 have in store for the big pharma?
(2d)
Building a smart oncology pipeline with Cumulus Oncology
(2d)
U.K. biotech ends on a high note in 2025 despite plummeting investments, report reveals
(4d)
U.K. biotech ends on a high note in 2025 despite plummeting investments, report reveals
(4d)
Seven Italian biotechs to know about in 2026
(4d)
How the University of North Carolina at Chapel Hill is enhancing RNAi potency with its new technology
(5d)
A clearer path to relief: sinusitis treatments on the way
(6d)
What does 2026 hold for the biotech industry?
(1w)
Top 5 trends that will drive biopharma in the next decade with Tim Opler
(1w)
Could CRISPR really cure these diseases?
(2w)
Bio IT World
Eli Lilly Gears Up for a Busy Year with a Diversified Pipeline
(3d)
Follow the Money: Helicon Peptide Development, Next-Gen Obesity Metabolic Disease Therapies, Cell Stress Sensing Platform
(4d)
BigHat, Revvity Collaborate with Eli Lilly, Immunai Signs Agreement with Bristol Myers Squibb, SandboxAQ Launches New AI Model
(5d)
Dealmakers Predict Banner Year as Biopharma M&A Momentum Builds
(1w)
Improved Drug Safety Needs Better Data Before AI
(1w)
AI in Pharma: Progress Made, But Data Challenges Persist
(2w)
10x Genomics Positions Spatial Biology as Center Stage as AI Fuels New Wave of Customer Demand
(3w)
Illumina at JPM 2026: Strong Q4, Clinical Growth, and BioInsight Launch
(3w)
PacBio at JPM 2026: Clinical Momentum and SPRQ-Nx Economics
(3w)
Oxford Nanopore at JPM 2026: Passing the Baton on a 20-Year Journey
(3w)
GEN News
StockWatch: C-Suite Shakeup, Phase III Plans Jolt Cardiff Investors
(9h)
Intranasal Bird Flu Vaccine Protects Against Highly Pathogenic Strains in Rodents
(12h)
Gut Microbes Shape Cancer Growth and Immunity Through Asparagine Metabolism
(2d)
Complex DNA Written at Scale, Genyro Licenses Caltech’s Sidewinder
(2d)
Ex-CEO Behind Bars, 10x’s Clinical Ambitions, Pharma’s AI Gambit
(2d)
Mosaic’s Nanoneedle Granted Advanced Manufacturing Technology Designation for Gene Therapy Products
(2d)
Twenty-Two Genes Could Hike Risk for Long-Term Health Issues After Epstein-Barr Infection
(2d)
DNA-Protein Crosslinks Drive Inflammation Linked to Early Aging
(3d)
Hippocampal Replay Persists but Loses Structure in Alzheimer’s Model
(3d)
Immunotherapy Reduces Plaque in Mouse Arteries, Suggesting Coronary Disease Intervention
(3d)
Cure Today
What MRD Testing Can Mean for Patients With Breast Cancer and Survivors
(7h)
A Patients Navigation Guide to Stage 2 Clear Cell Renal Cell Carcinoma
(11h)
Smoldering Multiple Myeloma: An Overview for Newly Diagnosed Patients
(1d)
Lung Carcinoid Tumors: Diagnosis, Staging and Treatment Options
(1d)
Key GI Cancer Advances from the 2026 ASCO Symposium
(2d)
Ibrance Adds 15 Months of Progression-Free Survival in HR+, HER2+ Breast Cancer
(2d)
Risk Assessment Remains Vital for Patients Even After Cancer Diagnosis
(2d)
The Last Walk Down the Hall: Reflections Before Entering Cancer Survivorship
(2d)
Biotin, Lab Interference and Safer Options for Cancer-Related Hair Loss
(2d)
FDA Accepts Ivonescimab Application for EGFR Lung Cancer
(2d)
Contract Pharma
Lilly to Build New Pennsylvania Manufacturing Facility
(2d)
Ardena Completes Divestment of Sweden Drug Substance Site to Nanologica
(2d)
Merz Therapeutics Taps Dan Staner as President, Region Europe
(2d)
Libris Innovations Taps Ramani Veranasi as CEO
(2d)
New Veeva Application Eliminates Paper, Streamlines Clinical Trial Data Flow
(3d)
Vetter to Build New Production Facility in Germany
(3d)
Opentrons Formally Announces James Atwood as CEO
(3d)
WuXi Biologics, Sinorda Biomedicine Partner to Advance SND006
(3d)
IQVIA to Share its DaaS+ Platform in Boehringer Ingelheim Collaboration
(3d)
Halozyme Acquires Surf Bio for up to $400M
(3d)
Pharma Times
CERo reports encouraging early data from phase 1 trial of CER‑1236
(3d)
ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
(3d)
Argo Biopharma doses first patient in phase 2b trial of BW‑20829
(4d)
Akari files new patent and advances second ADC targeting CEACAM5
(4d)
BioMed X launches kidney disease project in partnership with the government of Barbados
(5d)
Gedeon Richter UK takes over UK rights to cariprazine
(5d)
Otsuka Pharmaceutical’s Dawnzera receives EC approval for hereditary angioedema prevention
(6d)
Corcept Therapeutics’ relacorilant plus nab-paclitaxel shows positive results in ovarian cancer
(6d)
ErVimmune raises 17m euros in funding to develop cancer vaccine
(1w)
Book your tickets and join the PM Society for the 40th PM Awards on 20 March 2026
(1w)
Medcity News
Premise-Crossover Merger: Inside the $2B Push for a New Employer Health Model
(11h)
Is It Time to Change the Independent Dispute Resolution Process of the No Surprises Act?
(11h)
Medication Affordability Depends on Total Price Transparency
(11h)
2026 Is the Year of the Doctor-Patient Relationship
(12h)
Clinical Trial Holds Cast Doubt on Approval Chances of Regenxbio Gene Therapy for Rare Disease
(13h)
Healthcare Moves: A Monthly Summary of Hires, Exits and Layoffs
(2d)
4 Notable Health Tech Funding Announcements in January
(2d)
AstraZeneca Beefs Up in Metabolic Disease, Paying $1.2B to Partner on CSPC Obesity & Diabetes Meds
(2d)
Harnessing Clinical Expertise to Unlock Hospital Capacity
(2d)
Humanized AI: No Longer Optional for Digital Patient Engagement
(2d)
Chemical & Engineering News
Jan. 30 Policy Watch: EPA re-ups plan to ditch animal testing for certain chemicals
(2d)
AstraZeneca signs $18.5 billion weight-loss-drug deal with Chinese firm
(2d)
Ancient Romans used human feces to make medicines
(2d)
‘ACS Nutrition Science’ publishes first issue
(2d)
US ultraprocessed food policy accelerates with bipartisan support
(2d)
Deluge of petrochemicals from China swamps other Asian countries
(3d)
Dow to cut 4,500 positions in new restructuring
(3d)
Chemistry in Pictures: Fight ice with starfish skeletons
(3d)
Podcast: Behind the scenes of the chaotic COP30
(3d)
‘Nature’ robot chemist paper corrected, but some questions remain unanswered
(3d)
The Pharma Letter
The week in pharma: action, reaction and insight – week to January 30, 2026
(15h)
Kyowa Kirin to regain control of rocatinlimab
(1d)
Lundbeck presents new real-world data on Vyepti
(1d)
January 2026 batch of EMA/CHMP recommendations
(2d)
Strong quarter rounds off solid year for Regeneron
(2d)
David Berman to join Moderna executive team
(2d)
Recordati inks deal for Moderna drug
(2d)
AstraZeneca agrees obesity and T2D deal with CSPC
(2d)
Repertoire Immune inks deal with Lilly
(2d)
SpyGlass targets $150 million in IPO
(2d)
Targeted Oncology
Clinical Framing and Prognostic Assessment in Progressive Small Bowel Neuroendocrine Tumors
(13h)
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
(14h)
BI-1808 Plus Pembrolizumab Yield Antitumor Activity in Recurrent Ovarian Cancer
(1d)
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
(1d)
Ropeginterferon Alfa Gains NCCN Backing in Essential Thrombycythemia
(2d)
Ancestry Outpaces Race in Predicting HNSCC Biology, Survival
(2d)
Neoadjuvant Pembrolizumab Achieves High pCR Rates in Desmoplastic Melanoma
(2d)
Lirafugratinib NDA Seeks FDA Approval in Cholangiocarcinoma
(2d)
Multiomic Real-World Data Predict Outcomes in Metastatic Breast Cancer
(2d)
Selumetinib Granules Match Capsule Pharmacokinetics in Pediatric NF1-PN Study
(2d)
MedWatch
Employee representative leaves board of Novo Nordisk
(1d)
Eli Lilly plans to build a new factory in Pennsylvania for $3.5 billion
(1d)
Novo Nordisk’s director in China steps down
(2d)
Lundbeck shows strong performance again with best-selling migraine medication in new study
(2d)
Novo Nordisk nears EU approval for MASH drug
(2d)
Trump's online pharmacy is central to agreement with Novo Nordisk – launch now postponed
(2d)
Danish life science players on China train after confrontation with the US: "We must seek other avenues"
(2d)
AstraZeneca signs billion-dollar deal with Hong Kong-based CSPC for new slimming drugs
(2d)
Chinese biotech sector pressures Western rivals with rapid drug development
(2d)
Eli Lilly signs USD 1.84bn deal with Repertoire for new vaccines
(2d)
In The Pipeline
A New LLM System for Synthesis Planning
(2d)
Rev Up The Viral Factories!
(3d)
Add Up Those Energies
(4d)
The Disastrous US Vaccine Landscape
(5d)
Microstructures All Around
(1w)
Bearing Down on a Placebo Effect
(2w)
What Makes A Drug
(2w)
Good Old Bewildering GPCRs
(2w)
Are There Accumulating Microplastics in Human Tissue or Not?
(2w)
Farewell to Dibromoethane
(3w)
Pharmaphorum
EMA looks into 'data integrity' issue with Amgen's Tavneos
(2d)
FDA starts review of Summit's VEGFxPD-1 bispecific
(2d)
Three more biotechs price their Nasdaq IPOs
(2d)
GLP-1 drugs linked to pancreatitis, gallbladder problems
(2d)
AZ deepens Chinese ties, signs $18.5bn CSPC obesity deal
(2d)
Tenpoint eyes presbyopia drug launch after FDA nod
(3d)
Digital musculoskeletal care firm Sword buys rival Kaia
(3d)
Otsuka preps for July decision on centanafadine for ADHD
(3d)
Halozyme diversifies in drug delivery with Surf Bio buy
(4d)
Eikon prices its IPO, seeking to raise $318m
(4d)
Drug Discovery Weekly
AZ expands China operations, agrees obesity deal with CSPC
(2d)
This week in Drug Discovery (26 – 30 January)
(2d)
European Commission approves RSV vaccine
(2d)
Gedeon Richter announces transfer of neuropsychiatry product
(2d)
TECregen appoints Dr Klaas Zuideveld as CEO
(2d)
Partnership set to advance organoid-based disease models
(2d)
New obesity drug may cause fewer side effects, results show
(3d)
Genetic markers drive breast cancer drug resistance, study shows
(3d)
Parkinson’s could be identified in the blood, study shows
(3d)
Webinar: Mapping disease trajectories with proteomics
(3d)
HIT Consultant
MEDITECH Announces Passing of Founder Neil Pappalardo; Michelle O’Connor Named Interim Chair
(2d)
VA Allocates $1B for EHR Modernization as Part of Record FY26 NRM Spend
(2d)
Oracle May Cut 30k Jobs and Sell Cerner to Fund $156B OpenAI Deal
(2d)
Premise Health and Crossover Health Merge to Expand Advanced Primary Care
(2d)
Inside the $1.3B ”Smart Hospital”: How UCI Health and GW RhythmX Are Rewiring the Patient Experience
(2d)
Reimagining Care Delivery: 5 Imperatives for Operationalizing Enterprise-Wide RPM
(2d)
Beyond the Status Quo: 3 Core Pillars for Scaling a Private Practice in 2026
(2d)
AtlantiCare to Deploy Opmed.ai to Fix Surgical Scheduling Across Enterprise
(2d)
CB Insights Report: Digital Health Funding Hits $22.3B as 14 New Unicorns Emerge
(3d)
KLAS 2026 Rankings: Aledade and Guidehealth Named Top VBC Enablement Firms
(3d)
Insights: Pink Sheet
Public Complete Responses: US FDA Revised Corcept’s Letter To Fix Clarity, Not Facts
(2d)
Accelerated Approvals Perked Up While US FDA Excelled At Being Average In 2025
(2d)
Pink Sheet Podcast: Understanding US FDA’s CNPV Application Reviews
(2d)
Kygevvi & Kayshild Among Six Products To Get EMA Nod As Tavneos Faces Data Integrity Scrutiny
(2d)
EMA Backs Sanofi’s Rezurock After Initial Rejection On Advice From External Experts
(2d)
Japan’s Surprise Lower House Election May Bring Drug Pricing Reforms
(2d)
Innovation Appears Core Goal Of China’s Revised Drug Law
(3d)
US FDA Pushes Beyond Traditional Promotion, Challenges Microsoft Teams Background
(3d)
US Government Conditions DTC Drug Sales On Sponsors Putting No Conditions On Sales
(3d)
PDUFA VIII: Industry Proposes Releasing Redacted Action Packages For ‘All’ NDAs, BLAs
(3d)
BioXconomy
AstraZeneca makes $18.5bn bet on CSPC’s weight loss drugs
(2d)
Inside Chiesi’s rare disease partnership playbook
(2d)
Finding the opportunity in challenging times: Europe’s biotech landscape
(3d)
AbbVie strikes $100bn deal with Trump administration to boost US drug access and manufacturing
(4d)
Immuno Cure’s DNA-based HIV vaccine trial begins in China
(4d)
mRNA-antibody combination treatment keeps melanoma at bay, study finds
(4d)
Moderna does not ‘foresee investing’ in Phase III trials, says CEO
(4d)
Merck reportedly pauses acquisition talks with Revolution Meds amid valuation disputes
(4d)
Babies as ‘guinea pigs’: A vaccine trial in Guinea-Bissau comes under intense scrutiny
(5d)
Financial considerations in entering the Asian biotech market
(5d)
BioCentury
2026 Cardiovascular Catalysts: Lp(a) on the Horizon
(2d)
2026 Catalysts: Breakthrough progress in renal disease
(2d)
Eikon aims high for NASDAQ listing: Public Equity Report
(2d)
Survey results: What sponsors say is slowing cancer trials — and what’s helping
(2d)
AZ signals all-in on obesity via CSPC deal for $1.2B up front
(2d)
Obesity catalysts in 2026
(3d)
2026 Obesity Catalysts: Launches, readouts and challengers
(3d)
Venture bets, dealmaking key features of AZ’s China strategy
(3d)
Manufacturing companies Cellares, Antheia among the week’s fundings: Venture Report
(3d)
2026 Catalysts: The rise of RNAi
(4d)
SCRIP
Quick Listen: Scrip’s Five Must-Know Things
(13m)
Sun On ‘Disciplined’ M&A Approach, Day 1 Launch Readiness For Semaglutide In India
(2h)
Finance Watch: SPACs Attempt A Comeback As IPO Market Shows Signs Of Life
(2d)
Quince Therapeutics’ Fruit Spoils As Phase III A-T Study Falls To Ground
(2d)
Amgen Returns Eczema Drug To Kyowa Kirin On Marketability Doubts
(2d)
Roche Awaits Key Readouts In 2026 – Including Its Potential Biggest Ever Drug
(2d)
$10.7bn India OTC Opportunity Awaits Pharma, Will Regulatory Reform Flow?
(2d)
Sanofi’s Hudson Cuts Through Noise To Champion Vaccines
(2d)
Executives On The Move: Three CEOs And Four CFOs Among This Week’s Changes
(2d)
Positive Long-Term China Safety Data For Ascletis’s Oral Acne Contender
(2d)